Numerous compounds targeting purinergic receptors and/or integrins in clinical contexts are available to treat atherosclerosis, excessive inflammation, cancer, retinal neovascularization, and in age-related macular degeneration (61, 62, 63), so that repurposing these agents or a rational development of new inhibitor molecules can be foreseen as promising therapeutic alternatives to treat Serratia infections. This evidence concerns the gene P2RY1 and cancer.